(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 0.84% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.67%.
Novartis Ag's revenue in 2025 is $55,186,000,000.On average, 4 Wall Street analysts forecast NVS's revenue for 2025 to be $105,416,559,688,500, with the lowest NVS revenue forecast at $100,697,774,400,000, and the highest NVS revenue forecast at $109,389,500,784,000. On average, 4 Wall Street analysts forecast NVS's revenue for 2026 to be $107,396,660,157,300, with the lowest NVS revenue forecast at $102,012,250,500,000, and the highest NVS revenue forecast at $113,167,603,224,000.
In 2027, NVS is forecast to generate $109,565,052,067,800 in revenue, with the lowest revenue forecast at $105,734,986,200,000 and the highest revenue forecast at $113,271,270,669,000.